A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150
This study has been completed.
Sponsor:
Astellas Pharma Inc
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT01118559
First received: May 5, 2010
Last updated: NA
Last verified: May 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is to evaluate the effect of food on the pharmacokinetics of YM150 in healthy male adult subjects.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy Pharmacokinetics of YM150 |
Drug: YM150 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Crossover Assignment Masking: Open Label |
| Official Title: | Pharmacokinetic Study of YM150 - A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 |
Further study details as provided by Astellas Pharma Inc:
Primary Outcome Measures:
- Plasma concentration of YM150 and its metabolites [ Time Frame: for 3 days after drug administration ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Safety assessed by AEs, vital signs, 12-lead ECG and lab tests [ Time Frame: for 3 days after drug administration ] [ Designated as safety issue: No ]
- PT (prothrombin time) [ Time Frame: for 3 days after drug administration ] [ Designated as safety issue: No ]
- aPTT (activated partial thromboplastin time) [ Time Frame: for 2 days after drug administration ] [ Designated as safety issue: No ]
- FXa (factor Xa) activity [ Time Frame: for 1 days after drug administration ] [ Designated as safety issue: No ]
| Enrollment: | 24 |
| Study Start Date: | November 2009 |
| Study Completion Date: | January 2010 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: fast-fed sequence group
drug is administered in a fasted condition first, and fed-condition study follows
|
Drug: YM150
oral
|
|
Experimental: fed-fast sequence group
drug is administered in a fed condition first, and fasted-condition study follows
|
Drug: YM150
oral
|
Detailed Description:
To evaluate the effect of food on the pharmacokinetics of YM150 in healthy non-elderly adult male subjects using a 2×2 crossover design. Also, to evaluate the safety of YM150.
Eligibility| Ages Eligible for Study: | 20 Years to 44 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Body weight: ≥50.0 kg, <80.0 kg
- BMI: ≥17.6, <26.4
- Healthy, as judged by the investigator or sub-investigator based on the results of physical examinations and lab tests
Exclusion Criteria:
- Received any investigational drugs within 120 days before the study
- Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the study
- Received medication within 7 days before the study
- A deviation from the assessment criteria of physical examinations or laboratory tests
- A deviation from the normal reference range of coagulation test [PT or aPTT]
- History of drug allergies
- Upper gastrointestinal disease within 7 days before the study
- Concurrent or previous hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases
- Concurrent or previous malignant tumor
- Previous treatment with YM150
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Director, Astellas Pharma, Inc |
| ClinicalTrials.gov Identifier: | NCT01118559 History of Changes |
| Other Study ID Numbers: | 150-CL-019 |
| Study First Received: | May 5, 2010 |
| Last Updated: | May 5, 2010 |
| Health Authority: | Japan: Pharmaceuticals and Medical Devices Agency |
Keywords provided by Astellas Pharma Inc:
|
YM150 Food effect Healthy volunteer |
ClinicalTrials.gov processed this record on June 17, 2013